YTEN - Yield10 Bioscience, Inc - Research License deal mit Monsanto - 500 Beiträge pro Seite
eröffnet am 25.01.18 16:08:10 von
neuester Beitrag 08.03.21 14:51:26 von
neuester Beitrag 08.03.21 14:51:26 von
Beiträge: 65
ID: 1.272.535
ID: 1.272.535
Aufrufe heute: 0
Gesamt: 3.431
Gesamt: 3.431
Aktive User: 0
ISIN: US98585K8541 · WKN: A40A3X · Symbol: YTEN
6,0500
USD
+2,20 %
+0,1300 USD
Letzter Kurs 02:00:00 NYSE
Werte aus der Branche Chemie
Wertpapier | Kurs | Perf. % |
---|---|---|
9,2500 | +43,41 | |
1,4850 | +20,73 | |
49,47 | +12,74 | |
34,81 | +12,29 | |
12,900 | +9,97 |
Wertpapier | Kurs | Perf. % |
---|---|---|
1,9500 | -8,88 | |
30,42 | -10,00 | |
12,830 | -10,03 | |
0,7071 | -11,50 | |
1,7600 | -17,37 |
Bin heute hier eingestiegen. Sieht interessant aus. Insbesondere der research license deal mit Monsanto.
Im folgenden zwei News Releases aus jüngster Vergangenheit:
Yield10 Bioscience Grants Research License to Monsanto to Evaluate Two Novel Yield Traits in Soybean
GlobeNewswire•December 11, 2017
WOBURN, Mass., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (YTEN) announced today that it has granted a non-exclusive research license to Monsanto Company to evaluate its novel C3003 and C3004 yield traits in soybean. Under the license, Monsanto plans to research both traits within its soybean pipeline as a strategy to improve plant yields. Yield10 Bioscience is focused on "building better plants" by developing proprietary, breakthrough technologies that produce higher yields in major food and feed crops to enhance global food security using lower inputs of land, water and fertilizer.
https://yield10bioscienceinc.gcs-web.com/news-releases/news-…
Yield10 Bioscience Announces Pricing of $12.6 Million Public Offering
GlobeNewswire•December 19, 2017
WOBURN, Mass., Dec. 19, 2017 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (YTEN) today announced the pricing of an underwritten public offering of units for gross proceeds of $12.6 million, prior to deducting underwriting discounts and commissions and offering expenses payable by Yield10 Bioscience.
The offering is comprised of 3,828,000 Class A Units, priced at a public offering price of $2.25 per unit, with each unit consisting of one share of common stock, a five-year warrant to purchase one share of common stock at an exercise price of $2.25 per share, and a nine-month warrant to purchase 0.5 share of common stock at an exercise price of $2.25 per share, and 3,987 Class B Units, priced at a public offering price of $1,000 per unit, with each unit consisting of one share of preferred stock, having a conversion price of $2.25, five-year warrants to purchase 445 shares of common stock with an exercise price of $2.25 per share, and nine-month warrants to purchase 223 shares of common stock with an exercise price of $2.25 per share. The conversion price of the preferred stock issued in the transaction and the exercise prices of the warrants are fixed and do not contain any variable pricing features or any price based anti-dilutive features. The preferred stock issued in this transaction includes a beneficial ownership blocker but has no dividend rights (except to the extent that dividends are also paid on the common stock), liquidation preference or other preferences over common stock, and, with certain exceptions, has no voting rights. The securities comprising the units are immediately separable and will be issued separately. The closing of the offering is expected to take place on or about December 21, 2017, subject to the satisfaction or waiver of customary closing conditions.
https://yield10bioscienceinc.gcs-web.com/news-releases/news-…
Im folgenden zwei News Releases aus jüngster Vergangenheit:
Yield10 Bioscience Grants Research License to Monsanto to Evaluate Two Novel Yield Traits in Soybean
GlobeNewswire•December 11, 2017
WOBURN, Mass., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (YTEN) announced today that it has granted a non-exclusive research license to Monsanto Company to evaluate its novel C3003 and C3004 yield traits in soybean. Under the license, Monsanto plans to research both traits within its soybean pipeline as a strategy to improve plant yields. Yield10 Bioscience is focused on "building better plants" by developing proprietary, breakthrough technologies that produce higher yields in major food and feed crops to enhance global food security using lower inputs of land, water and fertilizer.
https://yield10bioscienceinc.gcs-web.com/news-releases/news-…
Yield10 Bioscience Announces Pricing of $12.6 Million Public Offering
GlobeNewswire•December 19, 2017
WOBURN, Mass., Dec. 19, 2017 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (YTEN) today announced the pricing of an underwritten public offering of units for gross proceeds of $12.6 million, prior to deducting underwriting discounts and commissions and offering expenses payable by Yield10 Bioscience.
The offering is comprised of 3,828,000 Class A Units, priced at a public offering price of $2.25 per unit, with each unit consisting of one share of common stock, a five-year warrant to purchase one share of common stock at an exercise price of $2.25 per share, and a nine-month warrant to purchase 0.5 share of common stock at an exercise price of $2.25 per share, and 3,987 Class B Units, priced at a public offering price of $1,000 per unit, with each unit consisting of one share of preferred stock, having a conversion price of $2.25, five-year warrants to purchase 445 shares of common stock with an exercise price of $2.25 per share, and nine-month warrants to purchase 223 shares of common stock with an exercise price of $2.25 per share. The conversion price of the preferred stock issued in the transaction and the exercise prices of the warrants are fixed and do not contain any variable pricing features or any price based anti-dilutive features. The preferred stock issued in this transaction includes a beneficial ownership blocker but has no dividend rights (except to the extent that dividends are also paid on the common stock), liquidation preference or other preferences over common stock, and, with certain exceptions, has no voting rights. The securities comprising the units are immediately separable and will be issued separately. The closing of the offering is expected to take place on or about December 21, 2017, subject to the satisfaction or waiver of customary closing conditions.
https://yield10bioscienceinc.gcs-web.com/news-releases/news-…
Link presentation Yield10 Bioscience Third Quarter 2017 Earnings Call
Nov 9, 2017
http://ir.yield10bio.com/static-files/c2f232f8-fee1-4f74-941…
Seite 13 value creation
Seite 15 upcoming milestones
Nov 9, 2017
http://ir.yield10bio.com/static-files/c2f232f8-fee1-4f74-941…
Seite 13 value creation
Seite 15 upcoming milestones
2.01+0.27 (+15.52%)
As of 12:03PM EST.
As of 12:03PM EST.
Hallo zusammen, bin neu auf den Wert aufmerksam geworden. Der Kurs war ja schon Mal deutlich höher. Wie kommt der tiefe Fall zu Stande?
ich war auch kurz vor dem einstieg in Yiel10 Bioscience Inc., bis mir hier aufgefallen ist, dass die bude nur den namen (vorher Metabolix) und das geschäftsmodell geändert hat.
sehr suspekt...
sehr suspekt...
Nice gain today
Habe heute hier wieder eine erste Position aufgebaut. Die Aktie ist sehr volatil und kann schnell auf $3 steigen. Cash reicht bis nächstes Jahr. Bis dahin werden meiner Ansicht nach genug News kommen, die für einen Kursanstieg sorgen werden. Time will tell...
http://ir.yield10bio.com/news-releases/news-release-details/…
"...the Company anticipates that its current cash resources will be sufficient to fund operations and meet its obligations for at least the next twelve months."
http://ir.yield10bio.com/news-releases/news-release-details/…
"...the Company anticipates that its current cash resources will be sufficient to fund operations and meet its obligations for at least the next twelve months."
Company presentation:
https://www.yield10bio.com/sites/default/files/YTEN_Investor…
„Has significant, near-term milestones in major row crops
• Data from field tests of C3003 in Camelina, canola and soybean expected in 2018
• Progressing oil enhancing traits using CRISPR genome editing“
https://www.yield10bio.com/sites/default/files/YTEN_Investor…
„Has significant, near-term milestones in major row crops
• Data from field tests of C3003 in Camelina, canola and soybean expected in 2018
• Progressing oil enhancing traits using CRISPR genome editing“
SeeThruEquity Issues Update on Yield10 Bioscience
22 March 2018
Price target of $8.50 for YTEN
https://finance.yahoo.com/news/seethruequity-issues-yield10-…
22 March 2018
Price target of $8.50 for YTEN
https://finance.yahoo.com/news/seethruequity-issues-yield10-…
Apr 24, 2018
Yield10 Bioscience Announces Plans for its 2018 Field Test Program
http://ir.yield10bio.com/news-releases/news-release-details/…
Yield10 Bioscience Announces Plans for its 2018 Field Test Program
http://ir.yield10bio.com/news-releases/news-release-details/…
Nice end of day trading action. Keep on radar...
Apr 26, 2018
Yield10 Addresses Application of Metabolic Engineering to Increase Crop Yield in Paper Published in Plant Science
Chief Science Officer Kristi Snell also confirmed as a keynote speaker at upcoming plant meeting
https://yield10bioscienceinc.gcs-web.com/news-releases/news-…
Yield10 Addresses Application of Metabolic Engineering to Increase Crop Yield in Paper Published in Plant Science
Chief Science Officer Kristi Snell also confirmed as a keynote speaker at upcoming plant meeting
https://yield10bioscienceinc.gcs-web.com/news-releases/news-…
May 8, 2018
Yield10 Researchers Publish Research in Plant Science Showing that Novel Transcription Factors Represent a Promising Approach for Increasing Crop Productivity
https://yield10bioscienceinc.gcs-web.com/news-releases/news-…
Yield10 Researchers Publish Research in Plant Science Showing that Novel Transcription Factors Represent a Promising Approach for Increasing Crop Productivity
https://yield10bioscienceinc.gcs-web.com/news-releases/news-…
Yield10 Bioscience's (YTEN) CEO Oli Peoples on Q1 2018 Results - Earnings Call Transcript
May.10.18
https://seekingalpha.com/article/4172681-yield10-biosciences…
"We ended first quarter of 2018 with $11.6 million in cash, cash equivalents and short-term securities on the balance sheet."
"We expect our cash on hand together with revenue expected under current government grants to support our operations to a number of technology proof points into mid-2019."
"Monsanto is the world leader in developing biotech traits in soybean. So it’s great to have them working in C3003 with a unique capabilities and capacity. Our new business model for working with ag major, its also attracted the interest of other parties for both additional gene traits as well as other crops. We have some discussions ongoing and our goal is to work with additional ag companies to bring forward new yield traits."
May.10.18
https://seekingalpha.com/article/4172681-yield10-biosciences…
"We ended first quarter of 2018 with $11.6 million in cash, cash equivalents and short-term securities on the balance sheet."
"We expect our cash on hand together with revenue expected under current government grants to support our operations to a number of technology proof points into mid-2019."
"Monsanto is the world leader in developing biotech traits in soybean. So it’s great to have them working in C3003 with a unique capabilities and capacity. Our new business model for working with ag major, its also attracted the interest of other parties for both additional gene traits as well as other crops. We have some discussions ongoing and our goal is to work with additional ag companies to bring forward new yield traits."
Yield10 Bioscience Exercises Option with University of Missouri to Obtain Exclusive Worldwide License to Advanced Technologies for Oilseed Crops
May 22, 2018
https://yield10bioscienceinc.gcs-web.com/news-releases/news-…
May 22, 2018
https://yield10bioscienceinc.gcs-web.com/news-releases/news-…
SeeThruEquity Issues Update on Yield10 Bioscience, Inc.
May 23, 2018 / SeeThruEquity, a leading independent equity research and corporate access firm focused on small-cap and micro-cap public companies, today announced it has issued an update on Yield10 Bioscience, Inc. (NASDAQ: YTEN).
https://www.accesswire.com/500588/SeeThruEquity-Issues-Updat…
No change to price target at this time ($8.50)
Our price target for YTEN is unchanged at this time. 1Q18 results set the stage for an important planting season, which should provide additional data for the company's portfolio of traits. We plan to re-evaluate the price target following results, a more expansive update of the Monsanto relationship, or more visibility into the company's other partnership discussions.
May 23, 2018 / SeeThruEquity, a leading independent equity research and corporate access firm focused on small-cap and micro-cap public companies, today announced it has issued an update on Yield10 Bioscience, Inc. (NASDAQ: YTEN).
https://www.accesswire.com/500588/SeeThruEquity-Issues-Updat…
No change to price target at this time ($8.50)
Our price target for YTEN is unchanged at this time. 1Q18 results set the stage for an important planting season, which should provide additional data for the company's portfolio of traits. We plan to re-evaluate the price target following results, a more expansive update of the Monsanto relationship, or more visibility into the company's other partnership discussions.
Yield10 Researchers Publish Research in Plant Cell Reports Describing the Development of its Camelina Platform as a Model Crop for Novel Yield Trait Discovery
June 21, 2018
https://globenewswire.com/news-release/2018/06/21/1527841/0/…
June 21, 2018
https://globenewswire.com/news-release/2018/06/21/1527841/0/…
July 12, 2018
Maxim Group analyst began coverage with a Buy rating on Yield10 Bioscience (YTEN) today and set a price target of $7.
https://hillaryhq.com/2018/07/12/maxim-group-covers-yield10-…
Maxim Group analyst began coverage with a Buy rating on Yield10 Bioscience (YTEN) today and set a price target of $7.
https://hillaryhq.com/2018/07/12/maxim-group-covers-yield10-…
Aug 8, 2018
Yield10 Bioscience Signs Research License Agreement Covering CRISPR-Cas9 Genome-Editing Technology with the Broad Institute and Pioneer
WOBURN, Mass., Aug. 08, 2018 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN), a Company developing new technologies to create step-change improvements in crop yield to enhance global food security, today announced it has signed a non-exclusive research license agreement jointly with the Broad Institute of MIT and Harvard and Pioneer, part of Corteva AgriscienceTM Agriculture Division of DowDuPont (NYSE - DWDP), for the use of CRISPR-Cas9 genome-editing technology for crops. The joint license covers intellectual property consisting of approximately 48 patents and patent applications on CRISPR-Cas9 technology controlled by the Broad Institute and Pioneer. Under the agreement, Yield10 has the option to renew the license on an annual basis and the right to convert the research license to a commercial license in the future, subject to customary conditions as specified in the agreement.
https://yield10bioscienceinc.gcs-web.com/news-releases/news-…
Yield10 Bioscience Signs Research License Agreement Covering CRISPR-Cas9 Genome-Editing Technology with the Broad Institute and Pioneer
WOBURN, Mass., Aug. 08, 2018 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN), a Company developing new technologies to create step-change improvements in crop yield to enhance global food security, today announced it has signed a non-exclusive research license agreement jointly with the Broad Institute of MIT and Harvard and Pioneer, part of Corteva AgriscienceTM Agriculture Division of DowDuPont (NYSE - DWDP), for the use of CRISPR-Cas9 genome-editing technology for crops. The joint license covers intellectual property consisting of approximately 48 patents and patent applications on CRISPR-Cas9 technology controlled by the Broad Institute and Pioneer. Under the agreement, Yield10 has the option to renew the license on an annual basis and the right to convert the research license to a commercial license in the future, subject to customary conditions as specified in the agreement.
https://yield10bioscienceinc.gcs-web.com/news-releases/news-…
Yield10 Bioscience Reports Promising Seed Yield Results for Novel Yield Trait C3004 in Growth Chamber Studies in Camelina
--Fast-Tracking Deployment of C3004 Trait into Canola and Soybean
WOBURN, Mass., Sept. 05, 2018 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN), a Company developing new technologies to create step-change improvements in crop yield to enhance global food security, today announced promising results for its novel yield trait C3004 in growth chamber studies conducted using its Camelina platform. Camelina plant lines containing C3004 grew vigorously, and the best lines produced increases in seed yield in a range of 26% to 65% as compared to control plants. Yield10 plans to conduct field tests of the C3004 trait in Camelina as part of its 2019 Field Test program in Canada. In addition, Yield10 is fast tracking deployment of the C3004 trait into canola and soybean to determine if the trait produces similar effects on plant vigor and seed yield in major oilseed crops.
“Our early research results with C3004 in Camelina including plant growth and vigor, branching and seed yield, though preliminary, are very encouraging,” said Kristi Snell, Ph.D., Chief Science Officer of Yield10 Bioscience. “These initial seed yield data for C3004 suggest we can harness the metabolic machinery of plants to drive robust increases in seed yield in Camelina. The next step is to determine if the effects of C3004 on plant vigor and seed yield can be successfully achieved in Camelina under field conditions and translated into canola, soybean and other commercial crops.”
https://globenewswire.com/news-release/2018/09/05/1565554/0/…" target="_blank" rel="nofollow ugc noopener">
https://globenewswire.com/news-release/2018/09/05/1565554/0/…
--Fast-Tracking Deployment of C3004 Trait into Canola and Soybean
WOBURN, Mass., Sept. 05, 2018 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN), a Company developing new technologies to create step-change improvements in crop yield to enhance global food security, today announced promising results for its novel yield trait C3004 in growth chamber studies conducted using its Camelina platform. Camelina plant lines containing C3004 grew vigorously, and the best lines produced increases in seed yield in a range of 26% to 65% as compared to control plants. Yield10 plans to conduct field tests of the C3004 trait in Camelina as part of its 2019 Field Test program in Canada. In addition, Yield10 is fast tracking deployment of the C3004 trait into canola and soybean to determine if the trait produces similar effects on plant vigor and seed yield in major oilseed crops.
“Our early research results with C3004 in Camelina including plant growth and vigor, branching and seed yield, though preliminary, are very encouraging,” said Kristi Snell, Ph.D., Chief Science Officer of Yield10 Bioscience. “These initial seed yield data for C3004 suggest we can harness the metabolic machinery of plants to drive robust increases in seed yield in Camelina. The next step is to determine if the effects of C3004 on plant vigor and seed yield can be successfully achieved in Camelina under field conditions and translated into canola, soybean and other commercial crops.”
https://globenewswire.com/news-release/2018/09/05/1565554/0/…" target="_blank" rel="nofollow ugc noopener">
https://globenewswire.com/news-release/2018/09/05/1565554/0/…
in Meinen Augen ist noch zu früh.
Sep 21, 2018
Yield10 Bioscience Grants Research License to Forage Genetics to Evaluate Novel Yield Traits in Sorghum
WOBURN, Mass., Sept. 21, 2018 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN), a Company developing new technologies to create step-change improvements in crop yield that enhance global food security, today announced that it has granted a non-exclusive research license to Forage Genetics International, LLC, a subsidiary of Land O’Lakes, Inc., to evaluate five novel yield traits in forage sorghum. Under the license, Forage Genetics plans to conduct research with the novel traits within its sorghum development program as a strategy to improve biomass yields.
http://ir.yield10bio.com/news-releases/news-release-details/…
Wikipedia:
Land O'Lakes ist eine Agrargenossenschaft US-amerikanischer Milchbauern mit Sitz in Minneapolis-St. Paul. Sie hat rund 3.600 direkte Mitglieder und rund 850 angeschlossene Genossenschaften mit über 300.000 Genossen (Stand 2013).[1]
Neben dem Geschäft mit Milchprodukten gehören auch der Futtermittelhersteller Purina Mills, der 2001 von Vorbesitzer Ralston Purina übernommen wurde,[2] sowie der Saatgut- und Pestizidhändler WinField Solutions zu Land O'Lakes
Yield10 Bioscience Grants Research License to Forage Genetics to Evaluate Novel Yield Traits in Sorghum
WOBURN, Mass., Sept. 21, 2018 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN), a Company developing new technologies to create step-change improvements in crop yield that enhance global food security, today announced that it has granted a non-exclusive research license to Forage Genetics International, LLC, a subsidiary of Land O’Lakes, Inc., to evaluate five novel yield traits in forage sorghum. Under the license, Forage Genetics plans to conduct research with the novel traits within its sorghum development program as a strategy to improve biomass yields.
http://ir.yield10bio.com/news-releases/news-release-details/…
Wikipedia:
Land O'Lakes ist eine Agrargenossenschaft US-amerikanischer Milchbauern mit Sitz in Minneapolis-St. Paul. Sie hat rund 3.600 direkte Mitglieder und rund 850 angeschlossene Genossenschaften mit über 300.000 Genossen (Stand 2013).[1]
Neben dem Geschäft mit Milchprodukten gehören auch der Futtermittelhersteller Purina Mills, der 2001 von Vorbesitzer Ralston Purina übernommen wurde,[2] sowie der Saatgut- und Pestizidhändler WinField Solutions zu Land O'Lakes
Oct 2, 2018
Yield10 Bioscience Obtains Nonregulated Status for its Novel CRISPR-Cas9 Triple Gene Edited Camelina Plant Lines to Boost Seed Oil Content
--USDA-APHIS Response Marks Clearance of Yield10’s First Triple Genome-edited Plant Lines
--Favorable Response Accelerates Path to U.S. Field Trials in 2019
http://ir.yield10bio.com/news-releases/news-release-details/…" target="_blank" rel="nofollow ugc noopener">
http://ir.yield10bio.com/news-releases/news-release-details/…
Yield10 Bioscience Obtains Nonregulated Status for its Novel CRISPR-Cas9 Triple Gene Edited Camelina Plant Lines to Boost Seed Oil Content
--USDA-APHIS Response Marks Clearance of Yield10’s First Triple Genome-edited Plant Lines
--Favorable Response Accelerates Path to U.S. Field Trials in 2019
http://ir.yield10bio.com/news-releases/news-release-details/…" target="_blank" rel="nofollow ugc noopener">
http://ir.yield10bio.com/news-releases/news-release-details/…
Antwort auf Beitrag Nr.: 58.854.537 von iknowtheway am 02.10.18 17:23:59Wenn Du auf AgriYieldBoosterEntwicklerFirmen stehst:
RKDA(.Lo) ist auch interessant.
Aber die Zeit ist NOCH nicht gekommen.
RKDA(.Lo) ist auch interessant.
Aber die Zeit ist NOCH nicht gekommen.
Antwort auf Beitrag Nr.: 59.153.250 von Popeye82 am 06.11.18 22:55:30Danke, interessanter Wert, werde ich mir mal genauer anschauen.
Bei YTEN hoffe ich auf baldige news. Die Field Test Ergebnisse dürften hoffentlich gut ausfallen.
Bei YTEN hoffe ich auf baldige news. Die Field Test Ergebnisse dürften hoffentlich gut ausfallen.
The Meteoric Rise of Genomics
November 8, 2018
https://www.agribusinessglobal.com/seeds-traits/the-meteoric…
November 8, 2018
https://www.agribusinessglobal.com/seeds-traits/the-meteoric…
Antwort auf Beitrag Nr.: 59.171.406 von iknowtheway am 08.11.18 19:08:22IknowTheWay
Was Mich mal interessieren würde.
Wie siehs Du persönlich denn Dieses "GMO" DIng?
Also aus der Beobachtung raus kann ich auf Jeden Fall sagen dass man "genetically modified organsims" in Den United States wohl ziemlich positiv, offensiv, aufgeschlossen gegenüber steht, in Europa/Deutschland eher sehr, sehr skeptisch. Das GANZE Gegenteil.
Also ich habe Eine Eigene Meinung, Dazu, will aber überhaupt nicht sagen Was jetzt "richtig" ist.
Aber ziemlich offensichtlich ist ja: Wenn weltweit gesehen demographisch nicht "Irgendwelche ganz Einschneidenden Sachen passieren", dass Wir in Einigen Sachen auf sehr, sehr, sehr Grosse Probleme zusteuern dürften. Wahrscheinlich richtig UGLY werden.
Also ich will Jetzt nicht sagen: "So ist es, und Anders nicht". Aber mal (D)Eine Sicht hören. In Bezug auf "GMO"s.
Was Mich mal interessieren würde.
Wie siehs Du persönlich denn Dieses "GMO" DIng?
Also aus der Beobachtung raus kann ich auf Jeden Fall sagen dass man "genetically modified organsims" in Den United States wohl ziemlich positiv, offensiv, aufgeschlossen gegenüber steht, in Europa/Deutschland eher sehr, sehr skeptisch. Das GANZE Gegenteil.
Also ich habe Eine Eigene Meinung, Dazu, will aber überhaupt nicht sagen Was jetzt "richtig" ist.
Aber ziemlich offensichtlich ist ja: Wenn weltweit gesehen demographisch nicht "Irgendwelche ganz Einschneidenden Sachen passieren", dass Wir in Einigen Sachen auf sehr, sehr, sehr Grosse Probleme zusteuern dürften. Wahrscheinlich richtig UGLY werden.
Also ich will Jetzt nicht sagen: "So ist es, und Anders nicht". Aber mal (D)Eine Sicht hören. In Bezug auf "GMO"s.
Antwort auf Beitrag Nr.: 59.172.549 von Popeye82 am 08.11.18 21:11:31Grundsätzlich habe ich mit der Technologie keine Probleme. Wenn ich das richtig verstehe, ist bei dem derzeitigen Bevölkerungswachstum eine Versorgung der Weltbevölkerung nur mit Gentechnik möglich, wenn überhaupt.
Rauchen ist so mit das ungesündeste, und das gibt man sich ja freiwillig...
Rauchen ist so mit das ungesündeste, und das gibt man sich ja freiwillig...
Genome Editing: Bioökonomierat fordert neues EU-Gentechnikrecht
Der Bioökonomierat legt eine differenzierte Bewertung der CRISPR-Technologie vor und appelliert an die Politik, das Gentechnikrecht zu modernisieren. Andernfalls bleibe Deutschland bei dieser „biologischen Revolution“ außen vor und werde auch die notwendige internationale Regulierung nicht mitgestalten.
09.10.2018
von Alfons Deter
https://www.topagrar.com/acker/news/genome-editing-biooekono…
Der Bioökonomierat legt eine differenzierte Bewertung der CRISPR-Technologie vor und appelliert an die Politik, das Gentechnikrecht zu modernisieren. Andernfalls bleibe Deutschland bei dieser „biologischen Revolution“ außen vor und werde auch die notwendige internationale Regulierung nicht mitgestalten.
09.10.2018
von Alfons Deter
https://www.topagrar.com/acker/news/genome-editing-biooekono…
To fulfill biofuels’ promise, scientists boost plant oils with gene editing
November 25, 2018
https://cen.acs.org/energy/biofuels/fulfill-biofuelspromise-…
...
To Peoples, the future looks promising. A 20% increase in the yield of conventional oil crops like canola and soybean could boost the economic value of these crops by $10 billion, he says. If the current techniques work well in camelina, the company will attempt similar gene edits in canola and soybeans.
Although Yield10’s primary goal is to sell its camelina oil for human health products and as an ingredient for agricultural animal feed rather than as a feedstock for biofuels, Peoples says the gene-editing discovery made by Yield10 could be beneficial for that type of application too.
Yield10 won’t disclose the exact edits its scientists made to improve camelina’s oil production, citing proprietary information. But presentation slides shared online on Nov. 4 for investors indicate that edits to genes that the firm calls C3008a, C3008b, and C3009 work to increase oil production by simultaneously increasing fatty acid biosynthesis and blocking the metabolism of the synthesized lipid.
At the same time, Yield10’s Canadian subsidiary, Metabolix Oilseeds, is working to edit a gene the company has called C3007 in camelina and canola. Gene C3007 encodes a protein that negatively regulates a key enzyme in fatty acid biosynthesis, acetyl-CoA carboxylase. By decreasing the activity of this negative regulator, the firm aims to boost the enzyme’s activity and make more plant oil.
...
November 25, 2018
https://cen.acs.org/energy/biofuels/fulfill-biofuelspromise-…
...
To Peoples, the future looks promising. A 20% increase in the yield of conventional oil crops like canola and soybean could boost the economic value of these crops by $10 billion, he says. If the current techniques work well in camelina, the company will attempt similar gene edits in canola and soybeans.
Although Yield10’s primary goal is to sell its camelina oil for human health products and as an ingredient for agricultural animal feed rather than as a feedstock for biofuels, Peoples says the gene-editing discovery made by Yield10 could be beneficial for that type of application too.
Yield10 won’t disclose the exact edits its scientists made to improve camelina’s oil production, citing proprietary information. But presentation slides shared online on Nov. 4 for investors indicate that edits to genes that the firm calls C3008a, C3008b, and C3009 work to increase oil production by simultaneously increasing fatty acid biosynthesis and blocking the metabolism of the synthesized lipid.
At the same time, Yield10’s Canadian subsidiary, Metabolix Oilseeds, is working to edit a gene the company has called C3007 in camelina and canola. Gene C3007 encodes a protein that negatively regulates a key enzyme in fatty acid biosynthesis, acetyl-CoA carboxylase. By decreasing the activity of this negative regulator, the firm aims to boost the enzyme’s activity and make more plant oil.
...
Interessanter Artikel über YTEN und CRISPR
November 30, 2018
http://www.wbur.org/commonhealth/2018/11/30/gene-edited-food…
November 30, 2018
http://www.wbur.org/commonhealth/2018/11/30/gene-edited-food…
Increasing Crop Yield Through Smart Approaches In Trait Discovery
December 3, 2018
https://sciencetrends.com/increasing-crop-yield-through-smar…
In Yield10’s research, the use of these models from the perspective of the company’s trait discovery and development program are detailed extensively, and one day may make significant impacts on the cost and timeline for developing new yield traits for major row crops – all of which could help in the challenge of addressing global food security challenges.
December 3, 2018
https://sciencetrends.com/increasing-crop-yield-through-smar…
In Yield10’s research, the use of these models from the perspective of the company’s trait discovery and development program are detailed extensively, and one day may make significant impacts on the cost and timeline for developing new yield traits for major row crops – all of which could help in the challenge of addressing global food security challenges.
Yield10 twitter account:
Yield10 Bioscience @Yield10Bio
We are thrilled that the segment in which we participated with @commonhealth / @WBUR on the use of CRISPR and gene/genome editing technologies to impact crop yield, was featured on @HereAndNow!
https://www.wbur.org/hereandnow/2018/12/10/gene-edited-food-…
Yield10 Bioscience @Yield10Bio
We are thrilled that the segment in which we participated with @commonhealth / @WBUR on the use of CRISPR and gene/genome editing technologies to impact crop yield, was featured on @HereAndNow!
https://www.wbur.org/hereandnow/2018/12/10/gene-edited-food-…
Dec 13, 2018
Yield10 Bioscience Names Sherri M. Brown, Ph.D., Former Monsanto Executive, as Special Commercial and Technical Advisor
WOBURN, Mass., Dec. 13, 2018 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN), a Company developing new technologies to create step-change improvements in crop yield that enhance global food security, today named Sherri M. Brown, Ph.D., as a special commercial and technical advisor to the Company, effective immediately. Dr. Brown is currently managing director of The Yield Lab, a global agrifood tech accelerator based in St. Louis. She previously served in a number of leadership positions involving the development and global commercialization of new biotechnology traits for canola, soybean and corn at Monsanto Company for 28 years.
https://yield10bioscienceinc.gcs-web.com/news-releases/news-…
Yield10 Bioscience Names Sherri M. Brown, Ph.D., Former Monsanto Executive, as Special Commercial and Technical Advisor
WOBURN, Mass., Dec. 13, 2018 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN), a Company developing new technologies to create step-change improvements in crop yield that enhance global food security, today named Sherri M. Brown, Ph.D., as a special commercial and technical advisor to the Company, effective immediately. Dr. Brown is currently managing director of The Yield Lab, a global agrifood tech accelerator based in St. Louis. She previously served in a number of leadership positions involving the development and global commercialization of new biotechnology traits for canola, soybean and corn at Monsanto Company for 28 years.
https://yield10bioscienceinc.gcs-web.com/news-releases/news-…
Antwort auf Beitrag Nr.: 59.432.211 von iknowtheway am 13.12.18 15:23:51Blonder,
Für Informationen,
vielleicht ein paar Zusätzliche,
kannst Du auch ---->Hier<---- mal reinsehen:
www.seethruequity.com/wp-content/uploads/2017/08/YTEN-INITIA…
www.seethruequity.com/research/
Für Informationen,
vielleicht ein paar Zusätzliche,
kannst Du auch ---->Hier<---- mal reinsehen:
www.seethruequity.com/wp-content/uploads/2017/08/YTEN-INITIA…
www.seethruequity.com/research/
Yield10 Bioscience (YTEN) Now Covered by National Securities
Jan 25th, 2019
https://www.modernreaders.com/news/2019/01/25/yield10-biosci…
Yield10 Bioscience logoInvestment analysts at National Securities initiated coverage on shares of Yield10 Bioscience (NASDAQ:YTEN) in a report issued on Wednesday, The Fly reports. The brokerage set a “buy” rating and a $5.00 price target on the specialty chemicals company’s stock.
Commercial Relationships In Early Stages. Since late 2017, two research license agreements have been reached with Monsanto and Forage Genetics International, major players in the soybean and sorghum markets, respectively. While these are research agreements for now, we believe these announcements validate Yield10’s technology and represent the kind of relationships that could generate commercial revenue.
High Ceiling Value. Between the value of the IP portfolio in the near term, and the potential value provided by commercial revenue streams, we believe shares of Yield10 could prove to be materially undervalued at current levels. Should commercialization agreements materialize, we believe our twelve month price target could prove to be conservative.”
Jan 25th, 2019
https://www.modernreaders.com/news/2019/01/25/yield10-biosci…
Yield10 Bioscience logoInvestment analysts at National Securities initiated coverage on shares of Yield10 Bioscience (NASDAQ:YTEN) in a report issued on Wednesday, The Fly reports. The brokerage set a “buy” rating and a $5.00 price target on the specialty chemicals company’s stock.
Commercial Relationships In Early Stages. Since late 2017, two research license agreements have been reached with Monsanto and Forage Genetics International, major players in the soybean and sorghum markets, respectively. While these are research agreements for now, we believe these announcements validate Yield10’s technology and represent the kind of relationships that could generate commercial revenue.
High Ceiling Value. Between the value of the IP portfolio in the near term, and the potential value provided by commercial revenue streams, we believe shares of Yield10 could prove to be materially undervalued at current levels. Should commercialization agreements materialize, we believe our twelve month price target could prove to be conservative.”
Wer zu Diesem "CRISPR" dümmer werden will, UNBEDINGT lesen!
www.abc.net.au/news/science/2016-04-07/crispr-gene-editing-t…
www.abc.net.au/news/science/2016-04-07/crispr-gene-editing-t…
YTEN Investor Presentation February 2019
http://ir.yield10bio.com/static-files/a105a7f1-3979-4775-8f6…
http://ir.yield10bio.com/static-files/a105a7f1-3979-4775-8f6…
GM-No? Yield10 Bioscience is Developing Gene-Edited Corn for Increased Yields
By
Catherine Lamb - February 25, 2019
https://thespoon.tech/gm-no-yield10-bioscience-is-developing…
By
Catherine Lamb - February 25, 2019
https://thespoon.tech/gm-no-yield10-bioscience-is-developing…
Mal sehen wie es weiter geht...
Antwort auf Beitrag Nr.: 59.858.047 von iknowtheway am 12.02.19 22:49:20YOU are not authorized to access this page.
Manchmal braucht man eben etwas Glück
Mein Verkaufsorder von 1,70 gestern hatte gezogen. Bin weiterhin von Yield10 überzeugt. Werde in den kommenden Woche wieder eine Position aufbauen.
Mar 15, 2019
Yield10 Bioscience Announces Pricing of $2.9 Million Registered Direct Offering
https://yield10bioscienceinc.gcs-web.com/news-releases/news-…
Mein Verkaufsorder von 1,70 gestern hatte gezogen. Bin weiterhin von Yield10 überzeugt. Werde in den kommenden Woche wieder eine Position aufbauen.
Mar 15, 2019
Yield10 Bioscience Announces Pricing of $2.9 Million Registered Direct Offering
https://yield10bioscienceinc.gcs-web.com/news-releases/news-…
Aug 12, 2019
Yield10 Bioscience Announces Notice of Allowance for U.S. Patent Covering Crop Yield Trait C4001
WOBURN, Mass., Aug. 12, 2019 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN), an agricultural bioscience company that uses its “Trait Factory” to develop high value seed traits for the agriculture and food industries, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office allowing its patent application covering the use of C4001 to improve productivity in crops.
https://yield10bioscienceinc.gcs-web.com/news-releases/news-…
Yield10 Bioscience Announces Notice of Allowance for U.S. Patent Covering Crop Yield Trait C4001
WOBURN, Mass., Aug. 12, 2019 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN), an agricultural bioscience company that uses its “Trait Factory” to develop high value seed traits for the agriculture and food industries, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office allowing its patent application covering the use of C4001 to improve productivity in crops.
https://yield10bioscienceinc.gcs-web.com/news-releases/news-…
Habe hier wieder in den vergangenen Wochen eine Position aufgebaut. Hoffe auf gute news in den kommenden Monaten.
Aug. 12, 2019
Yield10 Bioscience, Inc. (YTEN) CEO Oliver Peoples on Q2 2019 Results - Earnings Call Transcript
https://seekingalpha.com/article/4285013-yield10-bioscience-…
“CBD is a good example of a product targets for Yield10's traits and capabilities that considerable value for third-party with deep knowledge of the medical CBD business. Yet we're seeing a funded R&D program and upfront payments research funding and license revenues, as appropriate. These product targets provide opportunities for Yield10 to develop businesses that generate product revenue and/or partnerships of downstream revenue. We will keep you posted as it continues to make progress and finalize the business cases.”
“And we're also actively engaged in discussions with third parties interested in deploying our traits in a variety of other commercially important crops. We plan to keep you updated on the progress we're making all of these areas in the second half 2019.”
Aug. 12, 2019
Yield10 Bioscience, Inc. (YTEN) CEO Oliver Peoples on Q2 2019 Results - Earnings Call Transcript
https://seekingalpha.com/article/4285013-yield10-bioscience-…
“CBD is a good example of a product targets for Yield10's traits and capabilities that considerable value for third-party with deep knowledge of the medical CBD business. Yet we're seeing a funded R&D program and upfront payments research funding and license revenues, as appropriate. These product targets provide opportunities for Yield10 to develop businesses that generate product revenue and/or partnerships of downstream revenue. We will keep you posted as it continues to make progress and finalize the business cases.”
“And we're also actively engaged in discussions with third parties interested in deploying our traits in a variety of other commercially important crops. We plan to keep you updated on the progress we're making all of these areas in the second half 2019.”
Interessante Einschätzung von National Research.
Yield10 Bioscience’s (NASDAQ:YTEN) Buy Rating Reiterated at National Securities
Thursday, September 12th, 2019
https://rivertonroll.com/news/2019/09/12/yield10-bioscience-…
The firm currently has a $5.00 price target company’s stock.
- Additional Genes Now Under Consideration. The research license with Bayer (STU: BAY – NR – €66.48) has been amended to include an expanded scope for the C3004 trait. Under the original agreement signed in late 2017, BAY considered the C3003 and C3004 traits for evaluation in soybean, with the genes under consideration targeted to controlling carbon flow. With YTEN’s additional discoveries in the C3004 trait from 2018 trials in camelina, the research license was expanded to include a broader scope of genes.
- A Validation Of Technology? We expect that since the December 2017 license was signed that BAY has studied the C3003 and C3004 traits within its soybean varieties in greenhouse settings, and moved to field trials in Spring 2019. We believe that BAY could easily terminate the agreement if it saw no commercial potential, and we believe the expanded scope represents a validation of YTEN technology.
- No Better Commercial Partner. Following BAY’s acquisition of Monsanto, it controls roughly one third of global soybean sales, and its overall market share is significantly greater when considering seed distributed by peers which include BAY licensed traits. We believe of the major commercial crops that there is no better partner for YTEN than BAY and its soybean market.
- Additional Agreements Needed, May Come With Funded R&D. We anticipate that YTEN is in active discussions with other commercial partners and believe future research agreements may come with a funded R&D component.,” National Securities’ analyst wrote.
Yield10 Bioscience’s (NASDAQ:YTEN) Buy Rating Reiterated at National Securities
Thursday, September 12th, 2019
https://rivertonroll.com/news/2019/09/12/yield10-bioscience-…
The firm currently has a $5.00 price target company’s stock.
- Additional Genes Now Under Consideration. The research license with Bayer (STU: BAY – NR – €66.48) has been amended to include an expanded scope for the C3004 trait. Under the original agreement signed in late 2017, BAY considered the C3003 and C3004 traits for evaluation in soybean, with the genes under consideration targeted to controlling carbon flow. With YTEN’s additional discoveries in the C3004 trait from 2018 trials in camelina, the research license was expanded to include a broader scope of genes.
- A Validation Of Technology? We expect that since the December 2017 license was signed that BAY has studied the C3003 and C3004 traits within its soybean varieties in greenhouse settings, and moved to field trials in Spring 2019. We believe that BAY could easily terminate the agreement if it saw no commercial potential, and we believe the expanded scope represents a validation of YTEN technology.
- No Better Commercial Partner. Following BAY’s acquisition of Monsanto, it controls roughly one third of global soybean sales, and its overall market share is significantly greater when considering seed distributed by peers which include BAY licensed traits. We believe of the major commercial crops that there is no better partner for YTEN than BAY and its soybean market.
- Additional Agreements Needed, May Come With Funded R&D. We anticipate that YTEN is in active discussions with other commercial partners and believe future research agreements may come with a funded R&D component.,” National Securities’ analyst wrote.
Neben der Zusammenarbeit mit Bayer/Monsanto hat YTEN auch eine "Research License to Forage Genetics to Evaluate Novel Yield Traits in Sorghum" vergeben. Forage Genetics ist eine Tochtergesellschaft von Land O’Lakes, Inc. Laut Wikipedia beläuft sich der Jahresumsatz von Land O’Lakes auf 15 Milliarden US-Dollar. Hoffentlich kommen noch mehr solcher Ag industry collaborations.
Link: http://ir.yield10bio.com/node/14091/pdf
Link: http://ir.yield10bio.com/node/14091/pdf
Die Aktie könnte mal wieder gute news gebrauchen. 2019 field test results werden für Q4 erwartet.
Oct 23, 2019
Yield10 Bioscience Signs Research Agreement with J. R. Simplot to Evaluate New Traits to Produce High Yielding, Sustainable Potato Crop
https://yield10bioscienceinc.gcs-web.com/news-releases/news-…
Yield10 Bioscience Signs Research Agreement with J. R. Simplot to Evaluate New Traits to Produce High Yielding, Sustainable Potato Crop
https://yield10bioscienceinc.gcs-web.com/news-releases/news-…
Die Research License mit J. R. Simplot Company ist ein weiterer großer Gewinn für YTEN. Die J. R. Simplot Company ist ein milliardenschweres Unternehmen und ein großer Anbieter von Kartoffeln.
https://en.wikipedia.org/wiki/Simplot
Unter anderem ist die J. R. Simplot Company ein großer Lieferant von Pommes für McDonald's.
https://en.wikipedia.org/wiki/Simplot
Unter anderem ist die J. R. Simplot Company ein großer Lieferant von Pommes für McDonald's.
Habe heute nochmal Aktien nachgekauft. Mal sehen...
Nov 12, 2019
Yield10 Bioscience Announces Third Quarter 2019 Financial Results
WOBURN, Mass., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (NASDAQ:YTEN), an agricultural bioscience company that uses its “Trait Factory” to develop high value seed traits for the agriculture and food industries, today reported financial results for the three and nine months ended September 30, 2019.
https://yield10bioscienceinc.gcs-web.com/news-releases/news-…
Recent Progress Achieving 2019 Milestones
Expanded the research agreement with Bayer for evaluation of a new discovery related to the C3004 yield trait gene in soybean. Under the amended research license, Bayer will have access to new developments from Yield10’s C3004 program based on advanced technology related to the C3004 trait and its potential to increase seed yield.
Signed a research agreement with J. R. Simplot Company, to evaluate novel new traits to produce high yielding, sustainable potato crop. Under the agreement with Yield10, Simplot plans to conduct research with three yield traits (C3003, C3004, C4001) within its research and development program as a strategy to improve crop performance and sustainability. In addition to the three-year, non-exclusive research agreement, Simplot was granted an option to negotiate an exclusive commercial license agreement.
Presented research showcasing the Camelina Platform for producing PHB biomaterials to improve water quality. At the 3rd International Conference on Plant Synthetic Biology held in October, Yield10’s CSO Dr. Kristi Snell highlighted the scientific breakthrough achieved by Yield10 researchers demonstrating the ability to produce PHB biomaterials at the level of 10% of the mature seed weight in seeds of Camelina. PHB-producing Camelina can improve the sustainability of food production as a cover crop, by mitigating nutrient runoff at its source in the field, while also producing a PHB product for use as a denitrifying agent for water treatment that provides revenue to the farmer.
Yield10 Bioscience Announces Third Quarter 2019 Financial Results
WOBURN, Mass., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (NASDAQ:YTEN), an agricultural bioscience company that uses its “Trait Factory” to develop high value seed traits for the agriculture and food industries, today reported financial results for the three and nine months ended September 30, 2019.
https://yield10bioscienceinc.gcs-web.com/news-releases/news-…
Recent Progress Achieving 2019 Milestones
Expanded the research agreement with Bayer for evaluation of a new discovery related to the C3004 yield trait gene in soybean. Under the amended research license, Bayer will have access to new developments from Yield10’s C3004 program based on advanced technology related to the C3004 trait and its potential to increase seed yield.
Signed a research agreement with J. R. Simplot Company, to evaluate novel new traits to produce high yielding, sustainable potato crop. Under the agreement with Yield10, Simplot plans to conduct research with three yield traits (C3003, C3004, C4001) within its research and development program as a strategy to improve crop performance and sustainability. In addition to the three-year, non-exclusive research agreement, Simplot was granted an option to negotiate an exclusive commercial license agreement.
Presented research showcasing the Camelina Platform for producing PHB biomaterials to improve water quality. At the 3rd International Conference on Plant Synthetic Biology held in October, Yield10’s CSO Dr. Kristi Snell highlighted the scientific breakthrough achieved by Yield10 researchers demonstrating the ability to produce PHB biomaterials at the level of 10% of the mature seed weight in seeds of Camelina. PHB-producing Camelina can improve the sustainability of food production as a cover crop, by mitigating nutrient runoff at its source in the field, while also producing a PHB product for use as a denitrifying agent for water treatment that provides revenue to the farmer.
Habe heute am Ende des Handelstages wieder eine erste Position gekauft. Vermutlich werde ich meine Position weiter ausbauen in Abhängigkeit von der weiteren Kursentwicklung. Die aktuelle Marktkapitalisierung entspricht dem aktuellen Cash. Das Cash reicht bis ins zweite Quartal 2021. Dies sollte YTEN genügend Zeit geben, um einige Meilensteine zu erreichen, die den Aktienkurs ankurbeln können.
Yield10 Bioscience Secures Regulatory Permits for U.S. and Canadian Sites and Announces Plans for 2020 Field Test Program in Camelina and Canola
May 14, 2020
http://ir.yield10bio.com/node/15136/pdf
May 14, 2020
http://ir.yield10bio.com/node/15136/pdf
Bin heute raus mit 10% plus. Warte dann auf niedrigere Einstiegskurse...
Hier dürfte es bald gute Einstiegskurse geben. Gute Technologie, das Unternehmen ist immer für einen schnellen Doppler mit guten News zu haben...
Yield10 Bioscience Announces Pricing of $5.2 Million Public Offering and Concurrent Private Placement
August 23, 2020
WOBURN, Mass., Aug. 22, 2020 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq: YTEN), an agricultural bioscience company, todayannounced the pricing of its underwritten public offering of 835,000 shares of its common stock at a public offering price of $4.25 per share. The grossproceeds from the public offering will be approximately $3.5 million, before deducting underwriting discounts and commissions and estimated offeringexpenses. In addition, Yield10 also announced that investors affiliated with existing investor Jack W. Schuler, have agreed to purchase 396,450 sharesof Yield10’s common stock pursuant to a securities purchase agreement with Yield10 at the same price per share as in the public offering, in aseparate private placement transaction that is expected to close concurrently with the public offering. The gross proceeds from the private placementwill be approximately $1.7 million. All shares in the public offering and private placement are to be sold by Yield10.
http://ir.yield10bio.com/node/15331/pdf
Yield10 Bioscience Announces Pricing of $5.2 Million Public Offering and Concurrent Private Placement
August 23, 2020
WOBURN, Mass., Aug. 22, 2020 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq: YTEN), an agricultural bioscience company, todayannounced the pricing of its underwritten public offering of 835,000 shares of its common stock at a public offering price of $4.25 per share. The grossproceeds from the public offering will be approximately $3.5 million, before deducting underwriting discounts and commissions and estimated offeringexpenses. In addition, Yield10 also announced that investors affiliated with existing investor Jack W. Schuler, have agreed to purchase 396,450 sharesof Yield10’s common stock pursuant to a securities purchase agreement with Yield10 at the same price per share as in the public offering, in aseparate private placement transaction that is expected to close concurrently with the public offering. The gross proceeds from the private placementwill be approximately $1.7 million. All shares in the public offering and private placement are to be sold by Yield10.
http://ir.yield10bio.com/node/15331/pdf
Yield10 Bioscience Announces Participation at The H.C. Wainwright 22nd Annual Global Investment Conference on September 14-16, 2020 (Virtual Conference)
Oliver Peoples, Ph.D., President and Chief Executive Officer of Yield10, will provide an overview of the Company's business during the live presentation on Monday, September 14, 2020 at 11:00 am Eastern Time and will be available to participate in one-on-one meetings with investors who are registered to attend the conference.
https://finance.yahoo.com/news/yield10-bioscience-announces-…
Oliver Peoples, Ph.D., President and Chief Executive Officer of Yield10, will provide an overview of the Company's business during the live presentation on Monday, September 14, 2020 at 11:00 am Eastern Time and will be available to participate in one-on-one meetings with investors who are registered to attend the conference.
https://finance.yahoo.com/news/yield10-bioscience-announces-…
Antwort auf Beitrag Nr.: 65.045.967 von Malecon am 10.09.20 18:46:22Hier der mögliche Grund für den heutigen Anstieg...
With a current rating of Buy, HC Wainwright & Co. initiated coverage on Yield10 Bioscience Inc (NASDAQ: YTEN). The price target seems to have been set at $25.00 for Yield10 Bioscience. For the second quarter, Yield10 Bioscience had an EPS of $0.75, compared to year-ago quarter EPS of $0.15. The current stock performance of Yield10 Bioscience shows a 52-week-high of $14.69 and a 52-week-low of $0.11. Moreover, at the end of the last trading period, the closing price was at $4.35.
https://finance.yahoo.com/news/benzingas-top-upgrades-downgr…
With a current rating of Buy, HC Wainwright & Co. initiated coverage on Yield10 Bioscience Inc (NASDAQ: YTEN). The price target seems to have been set at $25.00 for Yield10 Bioscience. For the second quarter, Yield10 Bioscience had an EPS of $0.75, compared to year-ago quarter EPS of $0.15. The current stock performance of Yield10 Bioscience shows a 52-week-high of $14.69 and a 52-week-low of $0.11. Moreover, at the end of the last trading period, the closing price was at $4.35.
https://finance.yahoo.com/news/benzingas-top-upgrades-downgr…
Antwort auf Beitrag Nr.: 65.047.929 von iknowtheway am 10.09.20 21:40:44
Kursziel $ 25 ? Wow. Mama mia!
Zitat von iknowtheway: The price target seems to have been set at $25.00 for Yield10 Bioscience.
Kursziel $ 25 ? Wow. Mama mia!
Hohes Volumen heute...
Antwort auf Beitrag Nr.: 66.465.092 von iknowtheway am 15.01.21 21:41:36Was ist da los? Irgendein Durchbruch? Bin ab Montag auch mal dabei. Riesiges Potential, wenn sich da erstmal ein Hype lostritt.
https://www.genengnews.com/commentary/point-of-view/sowing-t…
Vom 8.1.21
Achtet auf diese Aussage!!!!!!!!!!!!
"Now, I know we still have lot of work ahead of us to develop commercial PHA Camelina varieties, but it’s only a matter of time before we can farm Camelina to produce natural PHA resin alternatives for plastic packaging materials and straws, knives, forks, and spoons. These can then be combined with food waste for biogas energy recovery, creating a closed-loop zero-waste system."
Stellt euch vor, der Firma gelingt dieser Durchbruch. Das würde die Plastikerzeugung für Verpackungen revolutionieren. Das könnte den Kurs 100fach ansteigen lassen! Dagegen sind die 45 MCap die jetzt erreicht wurden geradezu ein Witz. Die Branche ist generell noch sehr unter dem Radar.
https://www.genengnews.com/commentary/point-of-view/sowing-t…
Vom 8.1.21
Achtet auf diese Aussage!!!!!!!!!!!!
"Now, I know we still have lot of work ahead of us to develop commercial PHA Camelina varieties, but it’s only a matter of time before we can farm Camelina to produce natural PHA resin alternatives for plastic packaging materials and straws, knives, forks, and spoons. These can then be combined with food waste for biogas energy recovery, creating a closed-loop zero-waste system."
Stellt euch vor, der Firma gelingt dieser Durchbruch. Das würde die Plastikerzeugung für Verpackungen revolutionieren. Das könnte den Kurs 100fach ansteigen lassen! Dagegen sind die 45 MCap die jetzt erreicht wurden geradezu ein Witz. Die Branche ist generell noch sehr unter dem Radar.
So geht ein Ausbruch:
🎵
Antwort auf Beitrag Nr.: 66.478.010 von Malecon am 17.01.21 16:38:30Wenn sie nochmal auf 8-10 runterkommt, halt ich gegen
Antwort auf Beitrag Nr.: 66.478.010 von Malecon am 17.01.21 16:38:30Lasst euch von dem Aktienpreis nicht täuschen, die Marketcap liegt nun höher als 2017
Die Analysten halten die Aktie für unterbewertet:
Yield10 Bioscience – Consensus Indicates Potential 90.2% Upside
Yield10 Bioscience with ticker code (YTEN) now have 4 analysts in total covering the stock. The consensus rating is ‘Strong_Buy’. The target price ranges between 30 and 24 calculating the average target price we see 26.5. With the stocks previous close at 13.93 this would imply there is a potential upside of 90.2%.
https://www.directorstalkinterviews.com/yield10-bioscience--…
Chart #1:
Chart #2:
💡
Beitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Investoren beobachten auch:
Wertpapier | Perf. % |
---|---|
+1,56 | |
-1,72 | |
+0,29 | |
+1,32 | |
0,00 | |
+900,00 | |
+0,72 | |
-1,85 | |
+1,32 | |
+2,42 |
Meistdiskutiert
Wertpapier | Beiträge | |
---|---|---|
115 | ||
91 | ||
85 | ||
84 | ||
62 | ||
41 | ||
31 | ||
30 | ||
28 | ||
28 |